Individuals With Chronic Lymphocytic Leukemia Benefit More From iFCR Therapy Than Older Individuals

Name: Individuals With Chronic Lymphocytic Leukemia Benefit More From iFCR Therapy Than Older Individuals
Uploaded: 2021-12-13T17:30:00.000Z
Description: Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how the results of a longer term study differ for individuals who were younger with chronic lymphocytic leukemia as opposed to those who are older.

December 13, 2021

Video

Conference|ASH Annual Meeting and Exposition - American Society of Hematology Annual Meeting and Exposition

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how the results of a longer term study differ for individuals who were younger with chronic lymphocytic leukemia as opposed to those who are older.

In a Pharmacy Times® Interview, Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses his oral presentation at ASH 2021 of the Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia (CLL).

He discussed how the results of a longer term study differ for individuals who were younger as opposed to those who are older.